Fondazione Gimema Onlus

Transcriptomic profile and endothelial changes during differentiation syndrome in acute promyelocytic leukemia

Abstract Acute promyelocytic leukemia (APL) is curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), but differentiation syndrome (DS) remains a potentially life-threatening complication, with poorly understood pathogenesis. We investigated clinical, molecular a...

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Summary Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real‐world observational data outside randomized clinical trials remain limited...